Tag: RET inhibitor therapy

Home / RET inhibitor therapy

Categories

Selpercatinib is approved by FDA for RET fusion-positive thyroid cancer

  May 2024: The Food and Drug Administration has officially approved selpercatinib (Retevmo, Eli Lilly and Company) for the treatment of advanced or metastatic RET fusion-positive thyroid canc...
ret-inhibitor-therapy

Scan the code